Pulmonology

CHEST 2021: Among >7000 veterans diagnosed with lung cancer and scheduled for surgery, seeing a primary care doctor was linked to pre-operative quitting.

CHEST 2021: Study shows vaping raises the odds of developing asthma and COPD, especially in older adults, women, and Hispanic persons.

CHEST2021: The CHRONICLE study of biologics to treat severe asthma found reductions in exacerbations of more than 50% in patient groups not included in clinical trials.

In patients with severe asthma dependent on OCS, dupilumab reduced OCS dose and improved the odds of no longer requiring OCS, suggests research presented at CHEST 2021.

CHEST 2021: Patients with severe asthma who received tezepelumab compared with placebo demonstrated rapid improvement in morning and evening peak expiratory flow.

The long acting antibody combination reduced risk of severe disease or all-cause mortality by 50% in outpatients with high-risk comorbidities.

Two doses of the Pfizer COVID-19 vaccine also showed sustained efficacy of 93% against Delta-related hospital admission.

Janssen's investigational vaccine showed efficacy of up to 80% in preventing RSV-mediated lower respiratory tract infections in older adults.

COVID-19 case increases in the past 7 days range from 100% to 3.16% among the 10 states with the most significant rises. Is your state among these?

A variety of exposures in the work environment can cause asthma in some employees, according to new research presented at ERS Virtual International Congress 2021.

The albuterol/budesonide combination significantly reduced the risk of severe exacerbations and improved lung function in mild-to-moderate asthma.

Ivermectin has shown no clinical benefit for the many viral infections it has been studied in - including COVID-19. Why are patients buying it and physicians prescribing it?

Schaffner, medical director of the National Foundation for Infectious Disease, says we need to re-educate on the dangers of flu and "sell" the influenza vaccine to the vaccine-fatigued.

A new study found several risk factors associated with severe adult-onset asthma, including smoking, NSAID-exacerbated respiratory disease, and sibling count.

FDA approval of mezopelumab follows the phase 3 SYNAPSE trial in which the anti-Il-5 monoclonal antibody reduced by 57% the need for nasal polyp surgery.

Tezepelumab, a novel human monoclonal antibody that shows promise to reduce exacerbations across asthma phenotypes, was granted FDA Priority Review.

A new study found public health measures designed to curb COVID-19 transmissions may have fostered a significant side benefit: reduced COPD hospital admissions.

Four major cardiology organizations stand behind increased government action to eradicate tobacco use worldwide. Click here for a summary of why, why now, and how.

For patients with moderate-to-severe persistent asthma, new guidelines from the NAEPP recommend SMART, particularly for patients with a recent disease exacerbation.

ATS 2021: In a subgroup of oral corticosteroid-dependent patients with severe asthma from the newly released NAVIGATOR study, tezepelumab reduced exacerbations and improved lung function.

ATS.2021. Study authors categorized asthma patients using age at onset, T2 biomarkers, and IL-6 levels, creating 12 phenotypes for additional study.

ATS 2021: The risk of morbidity and death in patients with COPD increases among those with moderate exacerbation, and even more so for severe exacerbation, new research suggests.

In an abstract being presenting at the upcoming ATS 2021 International Conference, researchers estimate that by 2050 the US will lead the Americas in prevalence of COPD.

American Thoracic Society 2021 International Conference: In a subset of patients from the ETHOS study, triple combination therapy was found beneficial for those with moderate COPD.